Business Wire

CA-CHARGEPOINT-HOLDINGS

5.10.2022 09:01:38 CEST | Business Wire | Press release

Share
ChargePoint announces the CP6000, a global charging solution ready for the electric future

ChargePoint Holdings, Inc. (NYSE: CHPT), a leading electric vehicle (EV) charging network, today announced the launch of the CP6000, ChargePoint’s most flexible and serviceable global AC EV charging solution now available for vehicles of all types and sizes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005038/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Designed for the needs of the European market, the CP6000 is a complete charging solution for businesses and fleets that want to confidently and efficiently prepare for the future of electric mobility. Seamlessly integrating network software, station hardware and customer support, the CP6000 is designed to prepare businesses of all kinds across the globe for the next wave of EV adoption. The CP6000 is designed for scalability, flexibility, reliability, and a best-in-class driver experience, and offers reliable AC charging for 1 or 3 phase power at an adaptable output of 3.7 to 22kw per port.

“ChargePoint’s mission is to make the transition to electric mobility simple. As the result of ChargePoint’s experience shaping the charging industry over the past 15 years, we understand what is critical to station owners and drivers, including effortless charging experiences, scalable design, quality products and excellent service,” stated ChargePoint Chief Product Officer, Bill Loewenthal. “EV charging needs are universal, even if what and how we drive varies by geography. The CP6000 has been designed across our R&D facilities in North America and Europe to cater to the charging needs of businesses, fleets and EV drivers. Built on our decade-plus of experience serving EV drivers and all types of organisations, CP6000 has what businesses need to be part of the future of electric mobility.”

Superior driver experience

Whether charging is for employees, customers, visitors or a fleet, the driver is at the centre of it all, which is why the driver is at the centre of the CP6000 design. The top-rated ChargePoint app has over 200,000 active places to charge on its network globally, as well an additional 355,000 public places to charge through roaming integrations with other major networks. ChargePoint driver support is available in multiple languages, ensuring drivers across Europe receive the best experience possible. The addition of the CP6000 to ChargePoint’s network ensures drivers are easily able to find, use and pay for the charge they need, in the language and currency they prefer.

“The new CP6000 series is a great addition to an already strong contingent of reliable, software driven hardware we offer our clients,” stated Bruce Galliford, CEO at RAW Charging, one of the first customers to receive the new technology. “When ChargePoint expanded to Europe, we saw a company with the longevity, customer base, engineering prowess and experience to be a fit with our vision. Leaving the technology to ChargePoint, we can focus on deployment. We have more projects coming for Aviva Investors, Greene King, McArthurGlen and other customers. We’re currently planning strategic expansion across Europe working with organisations that have a portfolio of sites across the continent. This year we’ll be putting in four new sites per working day, and when you’re doing that, you want it to work flexibly and at scale.”

Part of ChargePoint's unified software platform

The CP6000 works seamlessly with ChargePoint’s software platform, which offers real-time visibility into revenue, energy costs and driver details, complete control over pricing and driver access, and actionable reporting with over 35 pre-built charts and reports. ChargePoint’s software also includes robust power management tools to automatically reduce energy costs, on-station video messages, and over 40 turnkey API integrations. The CP6000 is also fully compliant with Open Charge Point Protocol (OCPP) 2.01, the latest version of the open standard. Together, these features make it easy for customers to manage their charging program, reduce costs, improve utilisation, and prepare for the future.

Built for the future of electrification

ChargePoint believes demand for EV charging is poised for rapid growth. The CP6000 series’ modular design and forward-thinking technology supports flexible configurations and easy upgrades, making it the robust solution for scaling EV charging availability and maximising station value. It can be customised into dozens of configurations for multiple use cases or regions, offering options on sockets, cable management, branding, display, shuttering and more. This modularity allows the CP6000 to more easily support field replacements and service, while also offering advanced sensors for enhanced diagnostics and support.

The CP6000 has also been designed to operate on Europe's variety of power grids and regulations. For example, the CP6000 meets the UK government's requirements for contactless payment capabilities for all AC stations of 7.1kW and above.

The CP6000 is now available to order across dozens of ChargePoint operating countries. To learn more about deploying the CP6000 across your business, contact your ChargePoint sales representative or distributor.

About ChargePoint

ChargePoint is creating a new fueling network to move people and goods on electricity. Since 2007, ChargePoint has been committed to making it easy for businesses and drivers to go electric with one of the largest EV charging networks and a comprehensive portfolio of charging solutions available today. The ChargePoint cloud-based subscription platform and software-defined charging hardware are designed to include options for every charging scenario from home and multifamily to workplace, parking, hospitality, retail and transport fleets of all types. Today, one ChargePoint account provides access to hundreds of thousands of places to charge in North America and Europe. To date, more than 133 million charging sessions have been delivered, with drivers plugging into the ChargePoint network on average every second. For more information, visit the ChargePoint pressroom, the ChargePoint Investor Relations site, or contact ChargePoint’s North American or European press offices or Investor Relations.

CHPT-IR

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005038/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye